top of page
The latest news, trends, analysis, interviews and podcasts from the global food and beverage industry
DSM-Firmenich has announced the completion of the sale of its 100% equity interest in DSM Jiangshan Pharmaceutical to Jingjiang Cosfocus Health Technology. In June 2023, DSM-Firmenich announced a restructuring of its vitamin assets aimed at significant cost reduction. This included closing the Xinghuo vitamin B6 plant in China and shifting to focus solely on vitamin C activities, exclusively on Quali-C from Dalry (UK).
Vitamin C production in Jiangshan ceased completely in mid-May 2023, and the company said it was exploring options for the Jiangshan site, such as partnerships or repurposing manufacturing assets. Terms of the transaction were not disclosed.
Related posts
DSM-Firmenich offloads yeast business to Lesaffre
Meiji and DSM-Firmenich partner to reduce methane emissions
DSM-Firmenich and Deloitte partner on animal protein sustainability
DSM-Firmenich to separate Animal Nutrition & Health business
DSM-Firmenich receives approval for HMOs in infant formula in Australia and New Zealand
DSM-Firmenich unveils DelvoFresh Pioneer starter cultures
bottom of page